KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Taxes: 2012-2017

Historic Change in Taxes for Teva Pharmaceutical Industries (TEVA) over the last 4 years, with Mar 2017 value amounting to $54.0 million.

  • Teva Pharmaceutical Industries' Change in Taxes fell 76.32% to $54.0 million in Q1 2017 from the same period last year, while for Mar 2017 it was $347.0 million, marking a year-over-year decrease of 54.22%. This contributed to the annual value of $521.0 million for FY2016, which is 17.82% down from last year.
  • As of Q1 2017, Teva Pharmaceutical Industries' Change in Taxes stood at $54.0 million, which was down 5.26% from $57.0 million recorded in Q4 2016.
  • Teva Pharmaceutical Industries' Change in Taxes' 5-year high stood at $249.0 million during Q4 2015, with a 5-year trough of -$222.0 million in Q2 2013.
  • For the 3-year period, Teva Pharmaceutical Industries' Change in Taxes averaged around $134.3 million, with its median value being $104.0 million (2015).
  • Its Change in Taxes has fluctuated over the past 5 years, first surged by 1,233.33% in 2014, then plummeted by 77.11% in 2016.
  • Teva Pharmaceutical Industries' Change in Taxes (Quarterly) stood at $114.0 million in 2013, then soared by 63.16% to $186.0 million in 2014, then skyrocketed by 33.87% to $249.0 million in 2015, then plummeted by 77.11% to $57.0 million in 2016, then plummeted by 76.32% to $54.0 million in 2017.
  • Its Change in Taxes was $54.0 million in Q1 2017, compared to $57.0 million in Q4 2016 and $207.0 million in Q3 2016.